153 related articles for article (PubMed ID: 27390581)
1. Chronic Inflammation in Prostate Biopsy Cores is an Independent Factor that Lowers the Risk of Prostate Cancer Detection and is Inversely Associated with the Number of Positive Cores in Patients Elected to a First Biopsy.
Porcaro AB; Novella G; Mattevi D; Bizzotto L; Cacciamani G; Luyk ND; Tamanini I; Cerruto MA; Brunelli M; Artibani W
Curr Urol; 2016 May; 9(2):82-92. PubMed ID: 27390581
[TBL] [Abstract][Full Text] [Related]
2. Prostate chronic inflammation type IV and prostate cancer risk in patients undergoing first biopsy set: Results of a large cohort study.
Porcaro AB; Novella G; Balzarro M; Martignoni G; Brunelli M; Cacciamani G; Cerruto MA; Artibani W
Asian J Urol; 2015 Oct; 2(4):224-232. PubMed ID: 29264150
[TBL] [Abstract][Full Text] [Related]
3. Intraprostatic chronic inflammation is associated with a reduced risk of prostate cancer in patients elected to a first random biopsy set.
Porcaro AB; Novella G; de Luyk N; Corsi P; Cacciamani G; Sebben M; Tafuri A; Processali T; Cerasuolo M; Cerruto MA; Brunelli M; Siracusano S; Artibani W
Tumori; 2017 Sep; 103(5):475-482. PubMed ID: 27834470
[TBL] [Abstract][Full Text] [Related]
4. Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer.
Porcaro AB; Novella G; Molinari A; Terrin A; Minja A; De Marco V; Martignoni G; Brunelli M; Cerruto MA; Curti P; Cavalleri S; Artibani W
Urol Int; 2015; 94(3):270-85. PubMed ID: 25170543
[TBL] [Abstract][Full Text] [Related]
5. Chronic inflammation of the prostate type IV with respect to risk of prostate cancer.
Porcaro AB; Rubilotta E; Petrozziello A; Ghimenton C; Migliorini F; Zecchini Antoniolli S; Lacola V; Monaco C; Curti P; Cavalleri S; Pianon R; Artibani W
Arch Ital Urol Androl; 2014 Sep; 86(3):208-11. PubMed ID: 25308586
[TBL] [Abstract][Full Text] [Related]
6. Associations of Transitional Zone Volume with Intraprostatic Chronic Inflammation and Prostate Cancer Risk in Patients Undergoing a First Random Biopsy Set.
Porcaro AB; Mattevi D; Novella G; De Luyk N; Corsi P; Bizzotto L; De Marchi D; Sebben M; Tafuri A; Inverardi D; Processali T; Cerruto MA; Brunelli M; Siracusano S; Artibani W
Curr Urol; 2018 Feb; 11(2):85-91. PubMed ID: 29593467
[TBL] [Abstract][Full Text] [Related]
7. Prostatic chronic inflammation and prostate cancer risk at baseline random biopsy: Analysis of predictors.
Tafuri A; Sebben M; Novella G; Pirozzi M; Processali T; Shakir A; Rizzetto R; Amigoni N; Bernasconi R; Brunelli M; Cerruto MA; Siracusano S; Antonelli A; Artibani W; Porcaro AB
Arab J Urol; 2020 May; 18(3):148-154. PubMed ID: 33029424
[TBL] [Abstract][Full Text] [Related]
8. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume.
Remzi M; Fong YK; Dobrovits M; Anagnostou T; Seitz C; Waldert M; Harik M; Marihart S; Marberger M; Djavan B
J Urol; 2005 Oct; 174(4 Pt 1):1256-60; discussion 1260-1; author reply 1261. PubMed ID: 16145388
[TBL] [Abstract][Full Text] [Related]
9. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
[TBL] [Abstract][Full Text] [Related]
10. Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?
Albisinni S; Aoun F; Noel A; El Rassy E; Lemort M; Paesmans M; van Velthoven R; Roumeguère T; Peltier A
Prog Urol; 2018 Jan; 28(1):18-24. PubMed ID: 29203158
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer detection rates: comparison of standard biopsy with prompt rebiopsy and a one-time extended biopsy].
Türk Z; Hollberg H; Dill T; Kaspers I; Isbarn H
Urologe A; 2015 Jan; 54(1):28-33. PubMed ID: 25526851
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of an extended 21-core biopsy scheme as initial prostate cancer diagnostic strategy.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Vacherot F; Vordos D; Allory Y; Abbou CC; Salomon L; de la Taille A
Eur Urol; 2014 Jan; 65(1):154-61. PubMed ID: 22698576
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study.
Naughton CK; Smith DS; Humphrey PA; Catalona WJ; Keetch DW
Urology; 1998 Nov; 52(5):808-13. PubMed ID: 9801104
[TBL] [Abstract][Full Text] [Related]
14. Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study.
Moreira DM; Nickel JC; Andriole GL; Castro-Santamaria R; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):180-4. PubMed ID: 26782712
[TBL] [Abstract][Full Text] [Related]
15. The importance of active surveillance, and immediate re-biopsy in low-risk prostate cancer: The largest series from Turkey.
Bayar G; Horasanlı K; Acinikli H; Tanrıverdi O; Dalkılıç A; Arısan S
Turk J Urol; 2016 Sep; 42(3):140-4. PubMed ID: 27635287
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
[TBL] [Abstract][Full Text] [Related]
17. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
19. Prediction of tumour volume and pathological stage in radical prostatectomy specimens is not improved by taking more prostate needle-biopsy cores.
Grossklaus DJ; Coffey CS; Shappell SB; Jack GS; Cookson MS
BJU Int; 2001 Nov; 88(7):722-6. PubMed ID: 11890243
[TBL] [Abstract][Full Text] [Related]
20. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
